The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.
19 January 2015 | AllAfrica
On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.
14 January 2015 | HIV i-Base
A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.
13 January 2015 | CATIE
Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.
12 January 2015 | The Institute for Quality and Efficiency in Health Care
Waiting to start HIV treatment until 12 months after the estimated date of seroconversion decreases the likelihood of restoring the immune system.
07 January 2015 | AIDSMeds
The Zimbabwean government is with effect from this month switching all people on HIV treatment to a new one of one tablet per day from the previous three pills to make it easier for patients not to default on taking medication. The new single tablet has a combination of three drugs (Tenofovir/Lamivudine/Efavirenz TLE), a departure from the previous complicated treatment of three different tablets namely Tenofovir, Lovovidine and Nevirapine (TLN).
07 January 2015 | NewZimbabwe.com
Beginning treatment for HIV within a year of infection improves the likelihood of returning an individual’s CD4 count to a normal level.
03 December 2014 | AIDSMeds
Recommendations for a public health approach - December 2014 supplement to the 2013 consolidated ARV guidelines.
02 December 2014 | World Health Organization
Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.
25 November 2014 | The Body
This interim revision of the Guidelines includes a revised section on Hepatitis C Virus (HCV)/HIV Coinfection, with emphasis on considerations for use of antiretroviral (ARV) drugs in patients who also receive treatment for HCV infection. A new table (Table 12) provides clinicians with guidance on the concomitant use of HCV drugs and ARV drugs, with a focus on potential pharmacokinetic drug interactions. The Panel refers clinicians to http://www.hcvguidelines.org for guidance on the diagnosis and treatment of HCV infections.
17 November 2014 | AidsInfo